Company Overview and News

UPDATE 1-New Jersey Senate, Assembly passes nuclear subsidy bill

2018-04-12 reuters
April 12 (Reuters) - The New Jersey Senate and Assembly on Thursday passed a bill that would cost about $300 million a year to subsidize three nuclear reactors operated by New Jersey power company Public Service Enterprise Group Inc.
Upvote Downvote

Vexed by a Rocky Market? 5 Low-Beta Utility Picks to Rescue

2018-04-09 zacks
The lull in the markets with sporadic price swings is over. This year, the U.S. stock market has seen three of the Dow's major daily point drop in its 122-year history, including the 1,175-point record fall on Feb 5. Last Friday’s 572-point collapse has been another nail in the coffin. The U.S. stocks are witnessing massive volatility as investors apprehend a trade war from the bitter exchanges between the Unites States and China over tariffs.
Upvote Downvote

How FirstEnergy Is Placed amid Mounting Challenges

Ohio-based FirstEnergy (FE) is undergoing a transformation that its investors may cheerfully welcome. The company is having an eventful year so far. It’s received an investment from a leading activist investor, it’s asked for state aid to run its struggling power plants, and its riskier competitive subsidiary has filed for bankruptcy. The utility is focusing on becoming a pure-play regulated utility, which could stabilize its earnings in the long term.
Upvote Downvote

Charitable Giving by Corporations Is Also About Getting, a New Study Finds - The New York Times

2018-04-04 nytimes
Corporate philanthropy, business leaders would have us believe, is the ringing voice of a company’s social conscience. Exxon Mobil may stand accused of misleading investors and shareholders about what it knew about climate change, but the ExxonMobil Foundation’s multimillion-dollar contributions to end deaths from malaria and to train women in developing countries should, executives hope, balance the ethical ledger.
Upvote Downvote

DTE Energy (DTE) to Raise Generation Capacity in Michigan

2018-04-03 zacks
DTE Energy Company (DTE - Free Report) unveils plans to double its electricity generation capacity from renewable resources of energy in the State of Michigan by 2022. The proposal is part of the company’s 2018 Renewable Energy Plan, which was submitted to the Michigan Public Service Commission on Mar 30. The plan is in sync with DTE Energy’s earlier announced initiative to lower carbon emissions. Notably, the company projects to achieve this goal by reducing carbon emissions from its power plants up to 30%, 45%, 75% and more than 80% by early 2020s, 2030, 2040, and 2050, respectively.
Upvote Downvote

Top Analyst Upgrades and Downgrades: Autodesk, Boeing, Duke Energy, GameStop, Harley-Davidson, Hasbro, Mattel, Starbucks, Yandex and More

2018-03-29 247wallst
The markets closed down marginally on Wednesday, but the major indices were up on Thursday. The bull market is now over nine years old. While the trend of buying pullbacks has worked over and over, it now seems that the sellers and volatility are more influential than they have been in years. This is making it ever harder for investors to decide how they want their assets positioned for the rest of 2018 and beyond.
Upvote Downvote highlights: Verso, Covenant Transportation Group, Darling Ingredients, Ingles Markets and Exelon

2018-03-27 zacks
Chicago, IL – March 27, 2018 - Stocks in this week’s article include: Verso Corporation (VRS - Free Report) , Covenant Transportation Group, Inc. (CVTI - Free Report) , Darling Ingredients Inc. (DAR - Free Report) , Ingles Markets, Inc. (IMKTA - Free Report) and Exelon Corporation (EXC - Free Report) .
Upvote Downvote

5 Stocks With Strikingly Low EV/EBITDA Ratios to Own Now

2018-03-26 zacks
Investors typically have a fixation for the price-to-earnings (P/E) strategy in their quest for stocks that are trading at bargain prices. A widely favored approach by value investors is to chase stocks that have a low P/E ratio. But even this straightforward, broadly used valuation metric suffers a few downsides. EV/EBITDA is a Better Approach, Here’s Why While P/E is preferred by many investors while uncovering bargain stocks, another valuation metric called EV/EBITDA does a better job.
Upvote Downvote


UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) ☑ Filed by the Registra
Upvote Downvote


Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )
Upvote Downvote


kimco3342551-defa14a.htm - Generated by SEC Publisher for SEC Filing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) ☑
Upvote Downvote

Related Articles

RDHL: Redhill Biopharma Ltd (OTC:REDIF) Analysis and Research Report

2018-04-18 - Asif

History and Development of the Company The company's legal and commercial name is RedHill Biopharma Ltd. The company's company was incorporated on August 3, 2009, and was registered as a private company limited by shares under the laws of the State of Israel. The company's principal executive offices are located at 21 Ha’arba’a Street, Tel Aviv, Israel. In February 2011, the company completed its initial public offering in Israel, pursuant to which the company issued 14,302,300 Ordinary Shares, and 7,151,150 tradable Series 1 Warrants to purchase 7,151,150 Ordinary Shares for aggregate gross proceeds of approximately $14 million. On December 27, 2012, the company completed the listing of its ADSs on the NASDAQ Capital Market. The company's Ordinary Shares are traded on the Tel-Aviv Stock Exchange under the symbol “RDHL,” and its ADSs are traded on the NASDAQ Capital Market under the same symbol "RDHL". The company's capital expenditures for the years ended December 31, 2...

SCYX: SCYNEXIS Analysis and Research Report

2018-04-16 - Asif

Overview SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by delivering innovative anti-infective therapies. SCYNEXIS is developing its lead product candidate, SCY-078, as the first representative of a novel oral and intravenous (IV) triterpenoid antifungal family in clinical development for the treatment of several serious fungal infections, including invasive candidiasis, invasive aspergillosis, refractory invasive fungal infections and vulvovaginal candidiasis (VVC). SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo against a broad range of human fungi pathogens such as Candida and Aspergillus species, including multidrug-resistant strains, as well as Pneumocystis species. Candida and Aspergillus species are the fungi responsible for approximately 85% of all invasive fungal infections in t...

ENRT: Enertopia Corp (CNSX:TOP) Analysis and Research Report

2018-04-16 - Asif

Business History Enertopia Corp. was formed on November 24, 2004 under the laws of the State of Nevada and commenced operations on November 24, 2004. From inception until April 2010, the company were primarily engaged in the acquisition and exploration of natural resource properties. Beginning in April 2010, the company began its entry into the renewable energy sector by purchasing an interest in a solar thermal design and installation company. In late summer 2013, the company began its entry into medicinal marijuana business. During its 2014 fiscal year end its activities in the clean energy sector were discontinued. During fiscal 2015 its activities in the Medicinal Marijuana sector were discontinued. During fiscal 2016 its activities in the Women’s personal healthcare sector were discontinued. The Company is actively pursuing business opportunities in the resource sector, whereby the company signed a definitive agreement for a Lithium Brine Project in May 2016. In May ...

FB: Facebook Analysis and Research Report

2018-04-15 - Asif

Overview The company's mission is to give people the power to build community and bring the world closer together. The company's top priority is to build useful and engaging products that enable people to connect and share with friends and family through mobile devices, personal computers, and other surfaces. The company also help people discover and learn about what is going on in the world around them, enable people to share their opinions, ideas, photos and videos, and other activities with audiences ranging from their closest friends to the public at large, and stay connected everywhere by accessing its products, including: Facebook enables people to connect, share, discover, and communicate with each other on mobile devices and personal computers. There are a number of different ways to engage with people on Facebook, the most important of which is News Feed which displays an algorithmically-ranked series of stories and advertisements individualized for each pers...

VSTM: Verastem Analysis and Research Report

2018-04-12 - Asif

Business Overview Verastem is a biopharmaceutical company focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients. The company's most advanced product candidates, duvelisib and defactinib, utilize a multi-faceted approach to treat cancers originating either in the blood or major organ systems. Verastem is currently evaluating these compounds in both preclinical and clinical studies as potential therapies for certain cancers, including leukemia, lymphoma, lung cancer, ovarian cancer, mesothelioma, and pancreatic cancer. The company believe that these compounds may be beneficial as therapeutics either as single agents or when used in combination with immuno-oncology agents or other current and emerging standard of care treatments in aggressive cancers that are poorly served by currently available therapies. Duvelisib targets the Phosphoinositide 3-kinase (PI3K) signaling pathway. The PI3K signaling pathway plays a centr...

CUSIP: 30161N101